Dimensional Fund Advisors LP Boosts Stake in Emergent Biosolutions Inc. $EBS

Dimensional Fund Advisors LP lifted its holdings in Emergent Biosolutions Inc. (NYSE:EBS) by 22.4% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,757,158 shares of the biopharmaceutical company’s stock after buying an additional 504,553 shares during the period. Dimensional Fund Advisors LP owned approximately 0.05% of Emergent Biosolutions worth $22,884,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new stake in shares of Emergent Biosolutions during the first quarter valued at approximately $508,000. Values First Advisors Inc. grew its stake in Emergent Biosolutions by 0.9% in the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock valued at $2,555,000 after purchasing an additional 2,834 shares during the period. SG Americas Securities LLC increased its position in shares of Emergent Biosolutions by 4.6% during the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 1,865 shares during the last quarter. Evolve Private Wealth LLC purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $546,000. Finally, Baron Wealth Management LLC raised its stake in shares of Emergent Biosolutions by 40.2% during the 1st quarter. Baron Wealth Management LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 4,335 shares during the period. 78.40% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Emergent Biosolutions Price Performance

Emergent Biosolutions stock opened at $5.31 on Friday. The firm has a market capitalization of $273.97 million, a P/E ratio of -1.50 and a beta of 2.35. Emergent Biosolutions Inc. has a one year low of $5.06 and a one year high of $14.06. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. The business has a fifty day moving average price of $7.90 and a 200-day moving average price of $8.79.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 14.83% and a negative net margin of 22.95%.The business had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EBS. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Emergent reported adjusted EPS of $0.60, compared with the consensus estimate of a $0.08 loss, while revenue reached $234.3 million versus expectations of $177.5 million. Emergent Biosolutions: Q2 Earnings Snapshot
• Positive Sentiment: Biodefense demand remains a potential long-term catalyst: The company highlighted increased government and public-health attention to biological threats, including geopolitical conflict, synthetic biology and the possible misuse of biological agents. Cross-Sector Collaboration Against Biological Threats
• Neutral Sentiment: Management is undertaking a restructuring: The plan is part of broader turnaround efforts and includes layoffs, signaling an attempt to reduce costs and improve operating performance, but it may also create near-term disruption and expenses. Emergent BioSolutions Announces Restructuring
• Negative Sentiment: Full-year revenue guidance was cut well below analyst expectations: Emergent now expects 2026 revenue of $645 million to $675 million, compared with the consensus estimate of approximately $730.4 million. Emergent BioSolutions Shares Plunge After 2026 Guidance Cut
• Negative Sentiment: Third-quarter guidance was also materially below expectations: Revenue is projected at $110 million to $130 million, versus analyst expectations of about $209 million. The weak forward outlook and workforce reductions are driving the negative investor reaction despite the quarterly beat. Emergent Bio Slips Despite Q2 Beat After Guidance Cut

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.